EAMs are likely to have a major impact on the choice of TNFi versus IL-17A inhibitors in axSpA as there remains concern about the latter exacerbating IBD.35 36 In contrast, IL-17A inhibitors have been shown in head-to-head studies to have greater efficacy in psoriasis.37 38 It should be noted that to-date no head-to-head studies of biologics have been reported in axSpA, so data from observational studies will be required to help address these questions. The gene discussed is IL17A; the disease is inflammatory bowel disease.